Longevity Medicine
Moderate EvidencemTOR inhibition for lifespan extension — the most replicated result in aging research.
A physician's guide to rapamycin use in women — how mTOR signaling differs by sex, fertility implications, cycling strategies, and what the evidence actually shows.
Why most longevity physicians prescribe rapamycin in weekly pulses, not daily doses — covering mTOR biology, common protocols (1–6 mg/week), titration steps, and monitoring labs.
SGLT2 inhibitors extend lifespan in animal models and reduce all-cause mortality in humans. Here is what the evidence shows—and how they fit alongside rapamycin and metformin.
Metformin may impair mitochondrial adaptations to exercise in older adults. Learn who should cycle off, when to skip doses, and how to get the best of both.
A physician's guide to rapamycin contraindications for longevity use — covering immunosuppression, drug interactions, metabolic risks, and patient groups who should avoid it.
Acarbose extends lifespan in mice by 22% and is the most replicated ITP longevity drug. Here is what the evidence means for human longevity protocols.
How rapamycin targets mTOR in the liver to reverse diet-induced metabolic stress, protect hepatocytes, and what this means for longevity patients with metabolic risk.
Understand which rapamycin side effects apply at longevity doses versus transplant doses, what labs to monitor, and clear contraindications for off-label use.
How mTOR drives cellular aging, which compounds inhibit it, and why targeting this pathway is central to modern longevity medicine. Clinical overview by Dr. Julian Douwes.
A physician's evidence-based guide to rapamycin dosing for longevity: weekly intermittent protocols, dose ranges, lab monitoring, and who should avoid it.
A physician's honest comparison of rapamycin and metformin for longevity. mTOR inhibition vs AMPK activation, evidence quality, dosing, and who should use which.
How rapamycin inhibits mTOR to potentially slow aging. Evidence from animal studies, emerging human data, risks, and honest assessment.
